Dr. Jaime G. Deville, M.D.
Pediatric Infectious Disease (Pediatric Infectious Diseases Physician)
10833 Le Conte Ave, 12-441 Mdcc
Los Angeles, CA 90095
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
At a glance
- Years since graduation
- 41
- In the NPI registry since
- 2006
Licensed in California since 1992, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Infectious Diseases Physician primary
CA license A50817 (first issued 1992; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ronald Reagan UCLA Medical Center Los Angeles, CA
Medical groups
- UC Regents (93 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Biktarvy (bictegrav/emtricit/tenofov ala) | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 5 payments worth $2,570 in total to this clinician.
| Merck Sharp & Dohme LLC | $2,475 |
|---|---|
| Gilead Sciences, Inc. | $94.53 |
| Consulting Fee | $2,325 |
|---|---|
| Travel and Lodging | $150 |
| Food and Beverage | $94.53 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Apr 14, 2025 | Consulting Fee | $2,325 |
| Merck Sharp & Dohme LLC Apr 14, 2025 | Travel and Lodging travel to Los Angeles, CA | $150 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 11 industry-funded studies in 2025, from 7 companies. The companies reported $260,502 in research payments for these studies, mostly to the institutions running them.
- A phase 3 study to investigate the safety tolerability and immunogenicity of revaccinating pregnant participants during subsequent pregnancies and persistence of immunity of a single dose of a bivalent respiratory syn…
Pfizer Inc. - A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenof…
Gilead Sciences, Inc. - A Phase 1b Trial to Evaluate the Safety and Pharmacokinetics of Bictegravir/ Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Exposed Neonates
Gilead Sciences, Inc. - A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI)
Tetraphase Pharmaceuticals, Inc. · Recruiting · NCT06794541 - A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection
La Jolla Pharmaceutical Company · Recruiting · NCT06801223 - A phase 23 interventional safety pharmacokinetics and efficacy openlabel multicenter singlearm study to investigate orally administered PF07321332 nirmatrelvirritonavir in nonhospitalized symptomatic pediatric partici…
Pfizer Inc. - STUDY NAME#US RotaCare# Caregiver burden and family impact of rotavirus disease
Merck Sharp & Dohme LLC - A phase 3 randomized placebocontrolled doubleblinded trial to evaluate the safety tolerability and immunogenicity of a multivalent group b streptococcus vaccine in healthy pregnant women and their infants
Pfizer Inc. - STUDY NAME# US RotaCare# Caregiver burden and family impact of rotavirus disease
Merck Sharp & Dohme LLC - A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis
Melinta Therapeutics, LLC · Active, not recruiting · NCT06672978
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.